Compare AbbVie Inc (ABBV) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Kimberly Clark Corp — how do they compare? AbbVie Inc trades at $253.61 (market cap $449.91B), while Kimberly Clark Corp trades at $111.44 (market cap $38.09B). The key difference: AbbVie Inc is far larger — about 11.8× Kimberly Clark Corp's market cap, and Kimberly Clark Corp pays the higher dividend (4.46%). Which is the better fit depends on your goals.
| ABBV | KMB | |
|---|---|---|
Market Cap | $449.91B | $38.09B |
Sector | Health | Consumer Staples |
52-Week High | $261.07 | $136.77 |
52-Week Low | $184.85 | $93.05 |
Enterprise Value | $513.38B | $44.63B |
Dividend Yield | 2.72% | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
Kimberly-Clark (KMB) trades at $114.74, up 0.02% on the day, showing stable performance near its consensus price target. The stock maintains a bullish technical signal with strong moving average support, though oscillators indicate potential overbought conditions. Fundamentally, the company demonstrates consistent earnings beats with Q1 2026 EPS of $1.97 exceeding expectations, supported by a healthy 12.8% net income margin and robust ROE of 146.29%. Recent corporate actions include a $1.28 dividend payment scheduled for July 2026.
KMB presents a mixed outlook with strong profitability metrics offset by revenue declines from $20.4B in 2023 to $16.45B in 2025. Investment appeal includes a 5%+ dividend yield and analyst consensus leaning toward Hold (58.06%) with a $109.20 price target. Key risks include margin pressure from input costs and competitive threats from new market entrants like Arbex. Institutional sentiment remains cautious despite technical strength, requiring monitoring of Q2 2026 earnings due August 4, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
